HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Fructose 1,6-diphosphate administration attenuates post-ischemic ventricular dysfunction.

AbstractBACKGROUND:
Cardiomyocyte energy production during ischemia depends upon anaerobic glycolysis inefficiently yielding two ATP per glucose. Substrate augmentation with fructose 1,6-diphosphate (FDP) bypasses the ATP consuming steps of glucokinase and phosphofructokinase thus yielding four ATP per FDP. This study evaluated the impact of FDP administration on myocardial function after acute ischemia.
METHODS:
Male Wistar rats, 250-300 g, underwent 30 min occlusion of the left anterior descending coronary artery followed by 30 min reperfusion. Immediately prior to both ischemia and reperfusion, animals received an intravenous bolus of FDP or saline control. After 30 min reperfusion, myocardial function was evaluated with a left ventricular intracavitary pressure/volume conductance microcatheter. For bioenergetics studies, myocardium was isolated at 5 min of ischemia and assayed for ATP levels.
RESULTS:
Compared to controls (n=8), FDP animals (n=8) demonstrated significantly improved maximal left ventricular pressure (100.5+/-5.4 mmHg versus 69.1+/-1.9 mmHg; p<0.0005), dP/dt (5296+/-531 mmHg/s versus 2940+/-175 mmHg/s; p<0.0028), ejection fraction (29.1+/-1.7% versus 20.4+/-1.4%; p<0.0017), and preload adjusted maximal power (59.3+/-5.0 mW/microL(2) versus 44.4+/-4.6 mW/microL(2); p<0.0477). Additionally, significantly enhanced ATP levels were observed in FDP animals (n=5) compared to controls (n=5) (535+/-156 nmol/g ischemic tissue versus 160+/-9.0 nmol/g ischemic tissue; p<0.0369).
CONCLUSIONS:
The administration of the glycolytic intermediate, FDP, by intravenous injection, resulted in significantly improved myocardial function after ischemia and improved bioenergetics during ischemia.
AuthorsJeffrey E Cohen, Pavan Atluri, Matthew D Taylor, Todd J Grand, George P Liao, Corinna M Panlilio, Erik E Suarez, Suzanne E Zentko, Vivian M Hsu, Mark F Berry, Maximillian J Smith, Timothy J Gardner, H Lee Sweeney, Y Joseph Woo
JournalHeart, lung & circulation (Heart Lung Circ) Vol. 15 Issue 2 Pg. 119-23 (Apr 2006) ISSN: 1443-9506 [Print] Australia
PMID16469539 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Anti-Arrhythmia Agents
  • Cardiovascular Agents
  • Fructosediphosphates
  • Adenosine Triphosphate
  • Phosphofructokinase-1
  • 1-phosphofructokinase
  • fructose-1,6-diphosphate
Topics
  • Adenosine Triphosphate (metabolism)
  • Animals
  • Anti-Arrhythmia Agents (administration & dosage, metabolism)
  • Cardiovascular Agents (administration & dosage, metabolism)
  • Fructosediphosphates (administration & dosage, metabolism)
  • Glycolysis (drug effects)
  • Injections, Intravenous
  • Male
  • Models, Animal
  • Myocardial Ischemia (complications, enzymology)
  • Myocardial Reperfusion Injury (complications, drug therapy, enzymology)
  • Phosphofructokinase-1 (biosynthesis, drug effects, metabolism)
  • Rats
  • Rats, Wistar
  • Ventricular Dysfunction, Left (drug therapy, enzymology, etiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: